IP Library Granted Patent US 8,124,123
Granted Patent B2
US 8,124,123 · App. 12/002,417 · Granted Feb 28, 2012

Controlled release azithromycin solid dosages forms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,123
App. No.
12/002,417
Granted
Feb 28, 2012
Kind
B2
Abstract

A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.

Claims (48)

1. A controlled release solid oral dosage form comprising azithromycin in an amount that is 150 mg or less.

2. The oral dosage form of claim 1 which is a tablet.

3. The oral dosage form of claim 1 which is a capsule.

4. The oral dosage form of claim 1 wherein the amount is 100 mg or less.

5. The oral dosage form of claim 4 wherein the amount is 80 mg or less.

6. The oral dosage form of claim 1 wherein the dosage form is coated with an enteric coating.

7. The oral dosage form of claim 6 wherein the enteric coating includes a methacrylic copolymer.

8. The oral dosage form of claim 1 wherein the dosage form comprises a multiplicity of particles that are individually coated.

9. The oral dosage form of claim 8 wherein the coated particles have been formed into a solid that forms a part of or all of a tablet.

10. The oral dosage form of claim 8 wherein the coated particles are contained within a capsule shell.

11. The oral dosage form of claim 2 that comprises azithromycin, a disintegrating agent, a filler, and binding agent.

12. The oral dosage form of claim 11 which comprises dibasic calcium phosphate, croscarmellose sodium, hydroxypropylmethyl cellulose, and polyethylene glycol.

13. A controlled release solid oral dosage form comprising azithromycin in an amount of 150 mg or less from which dosage form not more than 50% of the azithromycin is released at pH 1 within one hour.

14. The solid oral dosage form of claim 13 from which not more than 25% of the azithromycin is released at pH 1 within one hour.

15. The solid oral dosage form of claim 13 from which not more than 10% of the azithromycin is released at pH 1 within one hour.

16. The solid dosage form of claim 13 which is a tablet.

17. The solid dosage form of claim 13 which is a capsule.

18. The oral dosage form of claim 13 wherein the amount is 100 mg or less.

19. The oral dosage form of claim 18 wherein the amount is 80 mg or less.

20. The oral dosage form of claim 16 that comprises azithromycin, a disintegrating agent, a filler, and binding agent.

21. The oral dosage form of claim 20 which comprises dibasic calcium phosphate, croscarmellose sodium, hydroxypropylmethyl cellulose, and polyethylene glycol.

22. A method for making a solid dosage form for oral administration containing azithromycin comprising combining azithromycin in an amount of 150 mg or less and one or more pharmaceutically acceptable excipients in a solid form and applying an enteric coating to the dosage form.

23. The method of claim 22 wherein the enteric coating is applied to the outer surface of the solid dosage form.

24. The method of claim 23 wherein the enteric coating is applied to individual particles containing azithromycin and the one or more pharmaceutically acceptable excipients within the solid oral dosage form.

25. The method of claim 22 wherein the solid dosage form is a tablet.

26. The method of claim 22 wherein the solid dosage form is a capsule.

27. A method for increasing the bioavailability of azithromycin from an oral solid dosage form containing azithromycin in an amount of 150 mg or less comprising providing said oral dosage form as a controlled release form.

28. The method of claim 27 wherein the oral dosage form is a tablet.

29. The method of claim 27 wherein the oral dosage form is a capsule.

30. The method of claim 27 wherein the amount is 100 mg or less.

31. The method of claim 30 wherein the amount is 80 mg or less.

32. The method of claim 27 wherein the dosage form is coated with an enteric coating.

33. The method of claim 32 wherein the enteric coating includes a methacrylic copolymer.

34. The method of claim 27 wherein the dosage form comprises a multiplicity of particles that are individually coated.

35. The method of claim 34 wherein the coated particles have been formed into a solid that forms a part of or all of a tablet.

36. The method of claim 34 wherein the coated particles are contained within a capsule shell.

37. The method of claim 28 wherein the dosage form comprises azithromycin, a disintegrating agent, a filler, and binding agent.

38. The method of claim 37 wherein the dosage form comprises dibasic calcium phosphate, croscarmellose sodium, hydroxypropylmethyl cellulose, and polyethylene glycol.

39. The oral dosage form of claim 5 wherein the amount is 60 mg.

40. The oral dosage form of claim 19 wherein the amount is 60 mg.

41. The method of claim 22 wherein 100 mg of azithromycin or less is combined.

42. The method of claim 41 wherein 80 mg of azithromycin or less is combined.

43. The method of claim 42 wherein 60 mg of azithromycin is combined.

44. The method of claim 31 wherein the amount is 60 mg.

45. The oral dosage form of claim 5 wherein the amount is 30 mg.

46. The oral dosage form of claim 19 wherein the amount is 30 mg.

47. The method of claim 42 wherein 30 mg of azithromycin is combined.

48. The method of claim 31 wherein the amount is 30 mg.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2019
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 049998/0734 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043046/0124 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.; ATON PHARMA, INC.
Reel/Frame 025950/0048 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2008
From: PILLAI, RADHAKRISHNAN; SARPOTDAR, PRAMOD; OSBORNE, DAVID W.; DOW, GORDON J.
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 020396/0111 →